Debiopharm, Marina Biotech to develop RNAi-based therapies for bladder cancer
LAUSANNE, Switzerland—The Debiopharm Group, a global independent biopharmaceutical development group of companies with a main focus in oncology and serious medical conditions, and Marina Biotech Inc., an RNAi-based drug discovery and development company, have entered into an exclusive agreement to advance to market an RNAi-based therapy for the treatment of non-muscle invasive bladder cancer.
Debiopharm, which will have full responsibility for the development and commercialization of any products arising from the partnership, will pay Marina Biotech up to $25 million based on predefined research and development milestones as well as royalties on the sales of products resulting from the partnership. In addition, all Marina Biotech research and development costs for the bladder cancer program will be funded by Debiopharm. Further terms of the agreement were not disclosed.